Company: HCWB
Filing Date: 2025-02-21
Form Type: 8-K
Source: 0000950170-25-024989
Chunk: 3

Company: HCW Biologics Inc.
Filing Date: 2025-02-21
Form: 8-K
Item: Item 9.01
Chunk 3
---
Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

  Exhibit No.      Description                                                                                                          
         10.1      Equity Purchase Agreement, dated February 20, 2025, between the Company and Square Gate Master Fund - Series 4.      
         10.2      Registration Rights Agreement, dated February 20, 2025, between the Company and Square Gate Master Fund - Series 4.  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
          104      Cover Page Interactive Data File (embedded within the Inline XBRL document).                                         

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                             HCW BIOLOGICS INC.                                 
  Date:      February 21, 2025      By:      /s/ Hing C. Wong                                   
                                             Hing C. Wong, Founder and Chief Executive Officer